EL7.AI
StocksMediumUpdated×2•Originally published 12 November 2026•Updated 13 November 2026•
4 min read

InspireMD Prices $37.5 Million Offering With Warrants to Purchase Additional Shares

Key Facts

1The priced offering had a stated aggregate value of $37.5 million on November 13, 2026.
2The offering includes 7,342,308 ordinary shares and pre-funded warrants to purchase 50,350,000 shares.
3Cash, cash equivalents and marketable securities totaled $19,246,000 on September 30, 2026.
4The company expects to begin U.S. sales of CGuard Prime for TCAR procedures in the fourth quarter of 2026.

InspireMD priced a public offering with an aggregate stated value of $37.5 million on November 13, 2026, after announcing the start of the process the previous day without specifying its size or terms. The offering includes 7,342,308 ordinary shares and pre-funded warrants to purchase 50,350,000 shares, along with ordinary warrants to purchase 43,269,231 shares or pre-funded warrants in their place. The company announced the pricing details after saying on November 12 that all securities offered would be issued by the company. At launch, it also said completion, timing, size and terms remained uncertain and depended on market conditions and other factors. The process thus moved within a day from a proposed offering with open terms to a priced offering with a stated value, while the possibility of completion remained tied to market conditions.

InspireMD appointed Lake Street Capital Markets as sole book-running manager, saying potential net proceeds would go toward research and development, sales and marketing, working capital and other general purposes. The announcement includes a proposed 30-day option for the underwriters to purchase additional securities equal to 15% of the total number of shares and pre-funded warrants sold. The company said the option relates to covering any over-allotments. These terms accompany the announced mix of securities, which combines ordinary shares, pre-funded warrants and ordinary warrants. The November 12 launch announcement did not specify a target value, while the disclosure the following day announced the priced offering’s value and the number of securities involved.

InspireMD’s offering came as third-quarter results showed revenue of $2.242 million, while cash, cash equivalents and marketable securities totaled $19.246 million on September 30, 2026. International revenue was $2.2 million, compared with $2.0 million in the third quarter of 2025, an annual increase of 9%. These figures place the liquidity reported at the end of September alongside the financing amount the company announced on November 13. InspireMD said potential offering proceeds would support research and development, sales and marketing, working capital and other general purposes, without allocating a specific amount to any of these uses. The disclosure does not provide a figure linking the offering proceeds directly to a defined period of operating funding.

The company is also seeking to restore its U.S. commercial activity after the Food and Drug Administration approved the CGuard Prime system for TCAR procedures, which it said returns the platform to the U.S. market. InspireMD expects to begin U.S. sales quickly in the fourth quarter of 2026. The company estimated that the approval enables it to target more than 35,000 TCAR procedures annually in the United States, while estimating that TCAR and CAS procedures combined total about 75,000 annually. These figures are based on the company’s market estimates. Chief Executive Marvin Slosman said the approval “expands the use of the CGuard implant to include TCAR procedures and is expected to provide a strong near-term growth driver,” presenting this as management’s expectation rather than a realized financial result.

The approval announcement was based on a U.S. pivotal, multicenter, single-arm study involving 50 patients at 11 research sites. InspireMD said the study recorded 100% acute device success during 30-day follow-up, with no deaths, strokes, myocardial infarctions or stent thrombosis. These results come from the study the company cited in announcing approval for use of the system in TCAR procedures. The expectation of starting sales during the fourth quarter follows a U.S. voluntary recall on May 1 of the 135-centimeter CGuard Prime delivery system. The company said at the time that the system’s performance during a controlled launch did not meet its expectations, and that the recall did not include the implanted stent.

In May, InspireMD withdrew its previous 2026 revenue guidance, linking the decision to the temporary halt in U.S. commercial activity pending the Food and Drug Administration approval then expected. In its results, the company said it expects to submit a supplement to its approval application to the agency in December 2026 regarding modifications to the CGuard Prime system for CAS procedures, with a possible relaunch in the first half of 2027. It also said the pivotal SwitchGuard trial continues to enroll participants. Regarding the offering’s structure, the company said on November 12 that it was being conducted under a shelf registration statement with file number 333-286309, filed on April 1, 2025, and declared effective on April 10 of the same year. It added that it would file a preliminary prospectus supplement and base prospectus, with final terms to be included in a final prospectus supplement.

Open on chart